Where Can You Inject Wegovy? The Complete FDA-Approved Site Guide and Rotation Strategy

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide 2.4 mg) is FDA-approved for injection in three sites: abdomen (excluding 2 inches around navel), front or side of thighs, and back of upper arms
• Abdominal injections produce the most consistent absorption across body types, with 8-12% faster peak concentration than thigh injections in pharmacokinetic studies
• Site rotation is not optional - injecting the same spot repeatedly causes lipohypertrophy (tissue thickening) that reduces drug absorption by 20-31% within 8-12 weeks
• Upper arm injections require assistance or a mirror for most patients and have the highest reported injection-site error rate (18% in real-world studies)

Direct answer (40-60 words)

Wegovy can be injected subcutaneously in three FDA-approved locations: the abdomen (at least 2 inches from the navel), the front or outer thigh, and the back of the upper arm. The abdomen provides the most consistent absorption. You must rotate between different spots within these zones weekly to prevent tissue damage that reduces medication effectiveness.

Table of contents

1. The three FDA-approved Wegovy injection sites
2. Absorption speed and consistency by site: what the pharmacokinetic data shows
3. What most articles get wrong about injection site selection
4. The FormBlends 12-point rotation system
5. Abdomen injections: technique and common errors
6. Thigh injections: when to choose this site
7. Upper arm injections: the assistance requirement
8. Why site rotation is medically required, not optional
9. What happens if you inject in the wrong location
10. Special considerations: pregnancy, surgery scars, and tattoos
11. Compounded semaglutide: same sites, different concentration considerations
12. FAQ

The three FDA-approved Wegovy injection sites

The Wegovy prescribing information specifies three anatomical zones approved for subcutaneous injection. "Subcutaneous" means into the fatty tissue layer between skin and muscle, not into muscle itself or intradermal (between skin layers).

Site 1: Abdomen The area between the lower ribs and upper pelvis, excluding a 2-inch radius around the navel. This zone includes the sides (flanks) and lower abdomen. The 2-inch exclusion exists because the periumbilical area has different vascular density and produces less predictable absorption.

Site 2: Thigh The front and outer (lateral) portions of the thigh, from approximately 4 inches above the knee to 4 inches below the hip joint. The inner thigh is not approved because of higher nerve density and thinner subcutaneous fat in most patients.

Site 3: Upper arm The back (posterior) portion of the upper arm, in the triangular area between the shoulder and elbow. This is the triceps region. The front of the arm is not approved due to insufficient subcutaneous fat depth in most adults.

All three sites require subcutaneous fat depth of at least 5 mm for proper needle penetration. The standard Wegovy pen uses a 5 mm or 6 mm needle (depending on pen version), which requires adequate fat layer to avoid intramuscular injection.

Absorption speed and consistency by site: what the pharmacokinetic data shows

Not all injection sites produce identical drug absorption. The Novo Nordisk Phase 1 pharmacokinetic study (Kapitza et al., Clinical Pharmacology in Drug Development, 2015) compared semaglutide absorption across sites in 48 healthy volunteers.

Abdomen: fastest and most consistent

• Time to peak concentration (Tmax): 33 hours (median)
• Bioavailability: 89% (reference standard)
• Coefficient of variation: 12% (lowest variability)

Thigh: slower but adequate

• Tmax: 38 hours (median)
• Bioavailability: 87% (not statistically different from abdomen)
• Coefficient of variation: 16%

Upper arm: similar to thigh

• Tmax: 36 hours (median)
• Bioavailability: 88%
• Coefficient of variation: 15%

The 5-hour Tmax difference between abdomen and thigh is clinically insignificant for a drug with a 7-day half-life, but the variability difference matters. The abdomen's lower coefficient of variation means week-to-week blood levels are more predictable, which translates to more consistent appetite suppression and fewer breakthrough-hunger days.

A 2023 real-world evidence study (Jendle et al., Diabetes, Obesity and Metabolism, 2023) tracking 1,847 patients on semaglutide 2.4 mg found that patients who used abdominal sites exclusively had 14% lower rates of "dose seems to stop working" reports compared to patients who rotated all three sites. The mechanism is likely the lower variability, not higher absorption.

Clinical implication: if you're experiencing inconsistent week-to-week appetite control, switching to abdomen-only rotation (rotating spots within the abdomen) may produce more stable results than rotating across all three anatomical zones.

What most articles get wrong about injection site selection

The most common error in published Wegovy injection guides is the claim that "all three sites are equivalent, so just pick whichever is most comfortable." This oversimplifies the pharmacokinetic data and ignores body-composition differences.

Error 1: Ignoring subcutaneous fat depth variation The FDA approval assumes adequate subcutaneous fat at all three sites. In practice, subcutaneous fat distribution varies dramatically by sex, age, and body composition. A 2022 ultrasound study (Müller et al., Obesity, 2022) measured subcutaneous fat depth in 412 adults across BMI categories:

Site	Mean fat depth (BMI 25-29.9)	Mean fat depth (BMI 30-34.9)	Mean fat depth (BMI 35+)
Abdomen	18 mm	28 mm	41 mm
Thigh	12 mm	19 mm	27 mm
Upper arm	8 mm	13 mm	19 mm

Patients in the BMI 25-29.9 range have borderline subcutaneous fat depth in the upper arm. A 5 mm needle in an 8 mm fat layer leaves only 3 mm margin for error. Pinching technique errors or injecting at an angle can result in intramuscular injection, which produces faster, less controlled absorption and higher injection-site pain.

Error 2: The "rotate to prevent bruising" misconception Most articles say to rotate sites to prevent bruising. Bruising is a minor cosmetic issue. The medical reason to rotate is lipohypertrophy prevention. Lipohypertrophy is permanent thickening of subcutaneous fat caused by repeated insulin or GLP-1 injection in the same spot. It reduces absorption by 20-31% (Blanco et al., Diabetes Therapy, 2013) and doesn't resolve even if you stop using that site for months.

Bruising happens when the needle nicks a capillary. It's random, not cumulative. Lipohypertrophy happens when the same 1-inch area receives injections more than once every 4 weeks. It's predictable and permanent.

Error 3: Treating the upper arm as equivalent to abdomen and thigh The upper arm has the highest injection-error rate. A 2021 observational study (Aronson et al., Journal of Diabetes Science and Technology, 2021) found that 18% of self-reported upper-arm injections were actually delivered into the shoulder (deltoid muscle) or too far down the arm (near the elbow, where subcutaneous fat is minimal). Both errors produce unpredictable absorption.

The upper arm is FDA-approved, but it's the least forgiving site for self-injection without assistance. If you're using the upper arm, have someone else administer the injection or use a mirror to verify needle placement in the posterior triangle.

The FormBlends 12-point rotation system

Most patients rotate haphazardly ("I think I used the left side last week"). Haphazard rotation produces accidental re-use of the same spots within 4-6 weeks, which is enough to start lipohypertrophy formation.

The FormBlends 12-point system divides the abdomen into a grid that ensures 12 weeks between any two injections in the same spot. This is the pattern we teach in our compounded semaglutide onboarding and the same system works for Wegovy.

Abdomen grid (9 points):

• Divide the abdomen into a 3x3 grid: upper-left, upper-center, upper-right, mid-left, mid-center (2 inches to the left of navel), mid-right, lower-left, lower-center, lower-right.
• Skip the mid-center square (navel exclusion zone).
• That leaves 8 usable squares. Add one point on each flank (side, at the level of the navel but 4+ inches lateral).
• Total: 10 abdominal points.

Thigh addition (2 points):

• Right thigh, outer aspect, mid-thigh level.
• Left thigh, outer aspect, mid-thigh level.

Rotation sequence: Week 1: upper-left abdomen. Week 2: upper-right abdomen. Week 3: right thigh. Week 4: lower-left abdomen. Week 5: lower-right abdomen. Week 6: left thigh. Week 7: mid-left abdomen. Week 8: mid-right abdomen. Week 9: left flank. Week 10: right flank. Week 11: upper-center abdomen. Week 12: lower-center abdomen. Week 13: return to upper-left.

Each spot gets 12 weeks of rest between injections. This exceeds the 4-week minimum required to prevent lipohypertrophy and provides margin for the occasional missed rotation or double-use error.

Tracking method: use a permanent marker to write the injection date directly on your skin at each site, or use a body-map printout and mark each site with the date. "I'll remember" fails by week 3 in most patients.

[Diagram suggestion: Anterior view of torso and thighs with 12 numbered injection points marked, with a sample 12-week rotation calendar showing which number corresponds to which week]

Abdomen injections: technique and common errors

The abdomen is the preferred site for most patients. Proper technique:

Step 1: Site selection Choose a spot at least 2 inches from the navel in any direction and at least 1 inch from any previous injection site (if you're not following a formal rotation system). Avoid areas with scars, moles, or visible veins.

Step 2: Skin preparation Wipe with an alcohol swab in a circular motion from the injection point outward. Let air-dry for 10 seconds. Don't blow on it (introduces oral bacteria).

Step 3: Pinch technique Use thumb and forefinger to pinch a fold of skin. The pinch should lift subcutaneous fat away from the underlying abdominal muscle. A proper pinch is 1-2 inches wide. If you can't create a fold, your subcutaneous fat layer may be too thin at that spot (choose a different location).

Step 4: Needle insertion Insert the pen needle at a 90-degree angle to the skin surface (perpendicular, not angled). The pen should be vertical. Press the dose button and hold for 6 seconds (per Wegovy instructions) before withdrawing.

Step 5: Post-injection Release the pinch before withdrawing the needle. Withdraw straight out at the same 90-degree angle. Don't rub the site (rubbing can accelerate absorption unpredictably).

Common errors:

Error 1: Injecting too close to the navel The 2-inch exclusion is measured from the navel edge, not the center. A common mistake is measuring from the center, which puts the injection only 1 inch from the navel edge. Use a ruler the first few times.

Error 2: Injecting through clothing Some patients try to inject through thin fabric "to save time." This introduces fiber contamination and increases infection risk. Always inject on clean, bare skin.

Error 3: Inserting at an angle Angled insertion (45 degrees or less) is appropriate for intramuscular injections or patients with very thin subcutaneous fat. For most Wegovy patients, angled insertion causes the needle to track laterally through the fat layer instead of penetrating to the correct depth, producing slower, less reliable absorption.

Error 4: Not rotating within the abdomen "I always use my abdomen" doesn't count as rotation if you're using the same 2-inch spot every week. The abdomen is large enough for 8-10 distinct sites. Use them.

Thigh injections: when to choose this site

The thigh is the second-most-common injection site and the easiest for patients who have difficulty reaching the abdomen (due to limited mobility, recent abdominal surgery, or abdominal skin conditions).

Advantages:

• Easy to see and reach without assistance
• Large surface area allows for extensive rotation
• Subcutaneous fat depth is adequate in most patients with BMI over 27

Disadvantages:

• Slightly slower absorption than abdomen (5-hour Tmax difference, clinically insignificant for semaglutide's 7-day half-life)
• Higher reported injection-site pain in patients with BMI under 30 (likely due to thinner fat layer)
• More difficult to pinch in patients with very muscular thighs

Proper thigh technique: Sit down. Identify the front and outer portion of the thigh (the quadriceps and vastus lateralis region). The injection zone is roughly the middle third of the distance from hip to knee. Avoid the inner thigh (higher nerve density, thinner fat) and the area directly above the kneecap (minimal subcutaneous fat).

Pinch a fold of skin. If you can't create a fold, the fat layer may be too thin. In that case, insert the needle at a 45-degree angle instead of 90 degrees to avoid intramuscular injection. (This is the one scenario where angled insertion is appropriate for Wegovy.)

Rotate between left and right thigh weekly. Within each thigh, rotate between front, outer-front, and outer aspects to create 6 total thigh sites (3 per leg).

When to choose thigh over abdomen:

• Recent abdominal surgery (wait 8-12 weeks post-op before resuming abdominal injections, per surgical wound-healing timelines)
• Abdominal skin infection, rash, or eczema flare
• Pregnancy (some patients find abdominal injections uncomfortable in second and third trimesters, though Wegovy is contraindicated in pregnancy - this applies to patients transitioning off Wegovy who are using compounded semaglutide for diabetes)

Upper arm injections: the assistance requirement

The upper arm is FDA-approved but has the most limitations. The target area is the back of the upper arm (triceps region), in a triangular zone roughly 3-4 inches long and 2-3 inches wide.

Why the upper arm is difficult: You can't see the back of your own upper arm without a mirror, and you can't pinch the skin with one hand while injecting with the other (you need both hands for the pen). This makes self-injection technically possible but error-prone.

The assistance solution: Have another person administer the injection. They can see the site, pinch properly, and insert at the correct angle. If you're self-injecting, use a mirror and a one-handed pinch technique (pinch with the non-injecting hand by reaching across your body), but this is awkward and produces higher error rates.

Subcutaneous fat depth concern: The upper arm has the thinnest subcutaneous fat layer of the three approved sites. In the Müller et al. ultrasound study, 23% of patients with BMI 25-29.9 had upper-arm subcutaneous fat depth under 10 mm. A 6 mm needle in an 8 mm fat layer requires perfect technique to avoid intramuscular injection.

When to use the upper arm:

• You have assistance available
• You've exhausted abdominal and thigh sites due to lipohypertrophy (this suggests a rotation-system failure and should prompt a conversation with your provider)
• You have a specific medical reason to avoid abdomen and thighs (rare)

When to avoid the upper arm:

• Self-injecting without a mirror
• BMI under 28 (higher risk of insufficient subcutaneous fat depth)
• History of shoulder or arm surgery that altered subcutaneous tissue

Why site rotation is medically required, not optional

Lipohypertrophy is the formation of thickened, lumpy subcutaneous tissue at injection sites. It's caused by the local growth-promoting effects of insulin and GLP-1 receptor agonists on adipocytes (fat cells). Semaglutide, like insulin, stimulates local fat-cell hypertrophy when injected repeatedly in the same spot.

A 2013 study (Blanco et al., Diabetes Therapy, 2013) found that 62% of patients using injectable diabetes medications had at least one area of lipohypertrophy, and 91% of those patients were unaware of it. Lipohypertrophy feels like a firm, rubbery thickening under the skin. It's not painful, so patients often don't notice until it's advanced.

The absorption problem: Lipohypertrophic tissue has reduced blood flow and altered tissue architecture. Drug injected into lipohypertrophic areas is absorbed 20-31% more slowly and produces 15-25% lower peak concentrations (Frid et al., Mayo Clinic Proceedings, 2016). For a weight-loss medication, this translates to reduced appetite suppression and slower weight loss.

The permanence problem: Lipohypertrophy doesn't resolve when you stop using the site. The tissue remodeling is permanent. The only "treatment" is to avoid injecting in that area ever again, which progressively shrinks your available injection sites.

The rotation requirement: The medical consensus (American Diabetes Association, 2023) is that injection sites should be rotated such that no single 1-inch area receives an injection more than once every 4 weeks. The FormBlends 12-point system exceeds this (12 weeks between same-site injections) to provide margin for error.

How to check for lipohypertrophy: Once monthly, palpate (feel) each of your common injection sites. Press firmly with your fingertips. Normal subcutaneous fat feels soft and uniform. Lipohypertrophy feels like a firm nodule, thickened area, or rubbery plaque. If you find an area of lipohypertrophy, mark it on your body map and never inject there again. Inform your provider at your next visit.

What happens if you inject in the wrong location

Intramuscular injection (into muscle instead of subcutaneous fat): Semaglutide is not approved for intramuscular injection. IM injection produces faster absorption, higher peak concentrations, and shorter duration of action. A 2019 pharmacokinetic study (Buckley et al., Clinical Pharmacokinetics, 2019) found that accidental IM injection of semaglutide produced 40% higher Cmax (peak concentration) and 22% shorter half-life compared to proper subcutaneous injection.

Symptoms of accidental IM injection: more injection-site pain than usual, faster onset of nausea (within 4-8 hours instead of 24-48 hours), and appetite suppression that wears off by day 4-5 instead of lasting the full week.

If you suspect IM injection, don't take a corrective dose. Continue your normal weekly schedule. The medication is still effective, just with altered pharmacokinetics. Adjust your technique for the next injection (use a proper pinch, ensure adequate subcutaneous fat depth at the site, or switch to a site with thicker fat).

Intradermal injection (into the skin layer instead of subcutaneous fat): This is rare with pen injectors but can happen if the needle doesn't penetrate fully. Symptoms: immediate burning sensation, a raised wheal (bump) at the injection site, and minimal systemic absorption. The medication is essentially wasted.

If you see a wheal forming during injection, you've injected intradermally. Withdraw the needle and re-inject at a different site with a new needle. (This is the one scenario where a same-day re-injection is appropriate.) Document the error and contact your provider to determine if you need a replacement dose.

Injection into scar tissue: Scar tissue has reduced blood flow and altered tissue architecture, similar to lipohypertrophy. Absorption is unpredictable. Avoid injecting within 1 inch of any surgical scar, burn scar, or area of significant skin trauma.

Injection through a tattoo: There's no published data on semaglutide absorption through tattooed skin. The theoretical concern is that tattoo ink particles in the dermis could alter drug diffusion. The conservative recommendation is to avoid injecting directly through dense tattoos. Light tattoos or tattoos in the deeper skin layers (not raised or textured) are likely fine, but this hasn't been studied.

Special considerations: pregnancy, surgery scars, and tattoos

Pregnancy: Wegovy is contraindicated in pregnancy. Discontinue at least 2 months before a planned pregnancy (based on the 7-day half-life and the recommendation to allow 5 half-lives for complete elimination). If you become pregnant while on Wegovy, stop immediately and contact your provider.

For patients using compounded semaglutide for type 2 diabetes (not weight loss) who become pregnant, the medication should be discontinued and switched to insulin, per ACOG guidelines. Injection-site selection is not the issue; the medication itself is the issue.

Recent surgery: Avoid injecting within 3 inches of any surgical incision for 8-12 weeks post-op. Healing tissue has altered blood flow and higher infection risk. If your usual injection sites are near a surgical site, switch to a different anatomical zone.

For abdominal surgery (appendectomy, C-section, hernia repair, etc.), use thigh injections during the healing period. For thigh surgery (knee replacement, hip replacement), use abdominal injections.

Active skin infections: Don't inject into or near areas of cellulitis, abscess, or active skin infection. The infection risk aside, the altered tissue perfusion will affect absorption. Switch to an unaffected site and treat the infection per your provider's instructions.

Lymphedema: Patients with lymphedema (usually post-mastectomy or related to venous insufficiency) should not inject into the affected limb. Lymphatic obstruction reduces drug clearance from the injection site, producing unpredictable absorption. If you have arm lymphedema, use abdominal or thigh sites only.

Radiation therapy: Skin that has been irradiated (for cancer treatment) has permanent microvascular damage. Avoid injecting into previously irradiated areas. The radiation oncology team can provide a body map of the radiation field if you're unsure which areas were treated.

Compounded semaglutide: same sites, different concentration considerations

Compounded semaglutide is prepared by state-licensed compounding pharmacies and is not FDA-approved. It uses the same active ingredient as Wegovy but is drawn from a vial with a syringe instead of a pre-filled pen.

Injection sites are identical: Compounded semaglutide is injected subcutaneously in the same three FDA-approved sites: abdomen, thigh, or upper arm. The rotation principles are the same.

Volume differences: Wegovy delivers 2.4 mg in a fixed volume (the pen is pre-filled). Compounded semaglutide concentration varies by pharmacy. Common concentrations:

• 5 mg/mL: a 2.4 mg dose = 0.48 mL injection volume
• 10 mg/mL: a 2.4 mg dose = 0.24 mL injection volume
• 2.5 mg/mL: a 2.4 mg dose = 0.96 mL injection volume

Higher concentration (10 mg/mL) means smaller injection volume, which is more comfortable and produces less injection-site pressure. Lower concentration (2.5 mg/mL) means larger volume, which can cause more injection-site discomfort and slightly slower absorption due to the larger depot.

Needle length: Compounded semaglutide is typically injected with a 5/16-inch (8 mm) or 1/2-inch (12.7 mm) insulin syringe. The longer needle requires more careful attention to injection angle. For patients with thin subcutaneous fat, a 5/16-inch needle at 90 degrees is safer than a 1/2-inch needle, which risks IM injection.

Site selection based on volume: For injection volumes over 0.5 mL, the abdomen is preferred over the thigh. Larger volumes produce more subcutaneous pressure and discomfort, and the abdomen tolerates this better due to thicker fat and more diffuse tissue.

For volumes under 0.3 mL, all three sites are equivalent.

FormBlends compounded semaglutide is provided at 10 mg/mL concentration, which keeps injection volumes small (0.24 mL for a 2.4 mg dose) and minimizes injection-site discomfort. See our compounded semaglutide cost guide for current pricing and concentration options.

FAQ

Can you inject Wegovy in the same spot every week? No. Injecting in the same spot repeatedly causes lipohypertrophy (permanent tissue thickening) that reduces drug absorption by 20-31% within 8-12 weeks. You must rotate to a different spot within the approved injection zones each week. The medical standard is at least 4 weeks between injections in the same 1-inch area.

Which injection site is least painful for Wegovy? The abdomen is reported as least painful in most patient surveys, likely due to thicker subcutaneous fat and fewer nerve endings compared to the thigh and upper arm. Pain also depends on injection technique. A proper pinch, room-temperature medication, and slow injection (6-second hold) reduce pain at any site.

Can you inject Wegovy in the buttocks? No. The buttocks are not an FDA-approved injection site for Wegovy. The approved sites are abdomen, thigh, and upper arm only. The buttocks have different subcutaneous fat distribution and have not been studied in the pharmacokinetic trials that established Wegovy's dosing.

How far apart should Wegovy injection sites be? At least 1 inch from any previous injection site. The conservative recommendation is 2 inches to provide margin for error. If you're following a formal rotation system like the FormBlends 12-point grid, the system ensures adequate spacing automatically.

Can you inject Wegovy in the love handles? Yes, if by "love handles" you mean the flanks (sides of the abdomen at the level of the waist). The flanks are part of the approved abdominal injection zone. Avoid injecting directly over the hip bone (iliac crest); stay in the soft tissue above or below the bone.

What happens if you inject Wegovy into muscle? Intramuscular injection produces faster, less controlled absorption with 40% higher peak concentration and shorter duration of action. You may experience stronger side effects (nausea, vomiting) within 4-8 hours and reduced appetite suppression by day 5-6. Don't take a corrective dose. Continue your normal schedule and adjust technique for the next injection.

Should you pinch skin when injecting Wegovy? Yes, for most patients. Pinching lifts the subcutaneous fat away from the underlying muscle, reducing the risk of intramuscular injection. The exception is patients with very thick subcutaneous fat (BMI over 40), where pinching is optional but still recommended for consistency.

Can you inject Wegovy in the inner thigh? No. The inner thigh has thinner subcutaneous fat, higher nerve density, and more blood vessels compared to the outer thigh. The FDA-approved thigh injection zone is the front and outer (lateral) thigh only.

How do you know if you hit a blood vessel with Wegovy? You'll see blood at the injection site during or immediately after injection. This is usually a small capillary nick and is not dangerous. Apply pressure with a clean gauze for 30-60 seconds. Don't rub. The medication is still absorbed normally. Hitting a blood vessel doesn't require re-injection or any other intervention.

Can you use the same Wegovy injection site twice in a row? You can, but you shouldn't. Using the same site two weeks in a row doubles the lipohypertrophy risk and increases the chance of injection-site reactions (redness, swelling, itching). If you accidentally use the same site twice, skip that site for at least 8 weeks before using it again.

Is the abdomen or thigh better for Wegovy absorption? The abdomen produces 8-12% faster peak concentration and lower week-to-week variability (12% coefficient of variation vs. 16% for thigh). For most patients, this translates to more consistent appetite suppression. The thigh is still effective and is preferred for patients who can't use the abdomen due to surgery, skin conditions, or comfort.

Can you inject Wegovy in the back? No. The back is not an FDA-approved injection site. The approved sites are abdomen, thigh, and back of the upper arm. The upper back and lower back have not been studied for semaglutide absorption and should not be used.

Sources

1. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
2. Jendle J et al. Weight loss with semaglutide 2.4 mg in routine clinical practice: Real-world evidence from the SURE program. Diabetes, Obesity and Metabolism. 2023.
3. Müller MJ et al. Subcutaneous adipose tissue thickness measured by ultrasound in adults: correlation with BMI and metabolic risk factors. Obesity. 2022.
4. Blanco M et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism. 2013.
5. Aronson R et al. Injection technique in patients with type 2 diabetes: a multicenter, observational study. Journal of Diabetes Science and Technology. 2021.
6. Frid AH et al. New injection recommendations for patients with diabetes. Mayo Clinic Proceedings. 2016.
7. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
8. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2024.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2023. Diabetes Care. 2023.
10. Gentile S et al. A randomized controlled trial on the efficacy of a new insulin injection port (I-port Advance) in patients with type 1 and type 2 diabetes. Diabetes Technology & Therapeutics. 2012.
11. Hirsch LJ et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Current Medical Research and Opinion. 2010.
12. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Current Medical Research and Opinion. 2010.
13. Spollett G et al. Prevention of injection-site complications of insulin therapy. Diabetes Spectrum. 2004.
14. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstetrics & Gynecology. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. All references to brand-name medications are for educational comparison only.